Chris DeMuth's State of the Markets June 2024

Episode Summary

Executive Summary: The episode centered on Chris Muth’s end-of-June market review, focusing on three investable themes: the delayed Liquidia/FDA decision, the declining effectiveness of Russell reconstitution arbitrage, and election-driven opportunities in merger arbitrage and housing/financial policy. Chris emphasized process discipline, skepticism about overanalyzing silence, and the idea that regulatory changes after the election could create the clearest trading setups.

Main Topics: Liquidia vs. UTHR and the FDA delay (Priority: 5/5): Chris argued the drug remains approvable and likely will be approved, but the FDA’s delay is largely about procedural friction with the court’s unusual requirement that the agency disclose decision timing before finalizing approval. He dismissed several UTHR tactics as low-probability distractions while acknowledging the binary nature of the stock. Ethical and practical challenges of biotech investing (Priority: 4/5): The conversation highlighted how difficult it is to analyze biotech because the medical problems are severe and emotionally weighty, while the technical details often exceed the investor’s expertise. Both speakers noted the moral discomfort of delays that affect patients. Russell reconstitution / index arbitrage has become harder (Priority: 4/5): Chris described Russell rebalance trading as once being a near-mechanical source of alpha, but now much more efficient, crowded, and prone to pricing in obvious outcomes early. He said the game shifted from exploiting easy mistakes to finding rare edge-case errors. Burford, Security National, and index inclusion edge cases (Priority: 4/5): The discussion used Burford and Security National as examples of how Russell-related outcomes can surprise the market. Burford’s drop despite expected index demand puzzled the speakers, while Security National illustrated a genuine market-cap reporting error that should have led to inclusion but did not. Post-debate election trades and policy sensitivity (Priority: 5/5): Chris said the election is increasingly likely to produce policy shifts relevant to investors, especially through executive action and regulatory changes rather than legislation. He sees the biggest opportunities in merger arbitrage and potentially Freddie Mac/Fannie Mae privatization if Trump wins. DJT, meme stocks, and tax-driven incentives in public office (Priority: 3/5): The hosts noted DJT trades in line with Trump’s odds of winning and joked about the implications of tax-free divestiture and capital gains rules for political actors. Chris used this to underscore how policy, incentives, and market structure intersect.

Key Arguments: Liquidia is still approvable; the main issue appears to be FDA delay and procedural conflict, not a substantive rejection. The FDA’s frustration with the court’s requirement to disclose timing before final decision creates a catch-22 and may be slowing approval. Biotech investing is hard not only because of technical uncertainty but because the underlying diseases are often devastating. Russell reconstitution used to be easy money, but quant competition and early pricing now make the trade much less reliable. The best Russell trades now are usually driven by mistakes, surprises, or misclassifications rather than standard additions/deletions. Election outcomes matter most through regulatory and executive action, not through sweeping legislation. Merger arbitrage spreads could benefit from a more deregulatory administration and from reduced probability of antitrust enforcement. Freddie Mac and Fannie Mae privatization could become more likely under Trump, especially if the key personnel are in place early. DJT is effectively a market proxy for Trump’s election odds, but it is still a meme-like, highly speculative vehicle. Policy incentives around taxation and capital gains create unusual distortions in political finance and personal behavior.

Data Points: Date of discussion: June 28, 2024 - Podcast recorded at the end of June during Chris Muth’s monthly market update Election debate date: June 27, 2024 - Referenced as the night before the conversation when discussing market implications Liquidia share price reference: About $16 to $13 per share - Burford example of market decline from early May to late June Burford trading volume: About 2 million shares/day - Used to highlight how unusual the Russell-related buying pressure should be Security National stock price: $7.71 - Mentioned near the Russell rebalance close Liquidia delay estimate: Months - Chris noted he thought FDA approval could have happened by March Russell rebalance performance: Worst performing in history - A source told Andrew the rebalance arb trade had its worst year ever Biden presidential outlook: At least 2 out of 3 likelihood he will not be president after February next year - Chris’s probabilistic view based on polling and betting markets Potential regulatory shift timing: Faster than taxes and spending - Chris argued executive/regulatory policy changes could happen relatively quickly after the election Matterport move: Up 6% - Attributed to merger-arbitrage expectations under a possible Republican administration Bonds/TLT move: Down about 1% - Used as an example of market reaction following the debate Russell cutoff example: Company 3002 - Security National missed inclusion by a narrow market-cap reporting error Expected Russell selling pressure: About a million shares - Chris said deleted names should face forced selling on rebalance day Trump privatization timing: Within a year or two - Chris’s estimate for a possible Freddie/Fannie privatization path if pursued early

Pivotal Quotes: "The number one tool is a robust training and development program." — Introductory sponsor read: Opening ad about Fundamental Edge corporate training "I think the FDA will approve it. I think it’s going to get to market. I think so fairly soon." — Chris Muth: His core view on Liquidia after discussing delay and regulatory uncertainty "It used to be almost just a mechanical money maker... Then it started getting hard, or I started getting bad." — Chris Muth: His reflection on how Russell reconstitution arbitrage has become more competitive and less reliable

Implications: Investors should focus on regulatory timing, election-driven policy shifts, and market structure changes rather than assuming old event-driven trades still work. The best opportunities now appear to be in nuanced, situation-specific dislocations, not broad mechanical arbitrage.